[Fundamental studies, reference values, and clinical evaluation of abnormal prothrombin PIVKA-II assay using monoclonal antibody (E-1023)].
作者信息
Sakurabayashi I, Kawai T, Omizo R, Hattori N, Ishii M
出版信息
Rinsho Byori. 1988 Dec;36(12):1407-12.
PMID:2854864
Abstract
摘要
相似文献
1
2
3
4
[Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].[血浆异常凝血酶原-II作为肝细胞癌新标志物的评估]
Gan No Rinsho. 1989 Apr;35(5):564-70.
5
[A staining method of PIVKA-II by an indirect immunoenzyme technic].[一种采用间接免疫酶技术检测异常凝血酶原（PIVKA-II）的染色方法]
Rinsho Byori. 1989 Oct;37(10):1139-42.
6
[Clinical signification and evaluation of PIVKA-II in hepatocellular carcinoma].[异常凝血酶原在肝细胞癌中的临床意义及评估]
Rinsho Byori. 1989 Jun;37(6):683-6.
7
Performance characteristics of the LiBASys des-gamma-carboxy prothrombin assay.LiBASys去γ-羧基凝血酶原检测的性能特征
Clin Chim Acta. 2008 Mar;389(1-2):183-5. doi: 10.1016/j.cca.2007.11.031. Epub 2007 Dec 7.
8
[Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
Rinsho Byori. 1998 Sep;46(9):936-41.
9
Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.血清异常凝血酶原（DCP）检测在鉴别肝脏良恶性疾病中的应用。
Anticancer Res. 1999 Jul-Aug;19(4A):2489-93.
10
[Clinical significance of des-gamma-carboxy prothrombin assay as a tumor marker].[去γ-羧基凝血酶原检测作为肿瘤标志物的临床意义]
Nihon Rinsho. 1990 Feb;48 Suppl:999-1002.
Zotero 插件